Literature DB >> 28535195

Presence of Type I-F CRISPR/Cas systems is associated with antimicrobial susceptibility in Escherichia coli.

Seyid Aydin1, Yoann Personne1, Enas Newire2, Rebecca Laverick1, Oliver Russell1, Adam P Roberts2,3, Virve I Enne1.   

Abstract

Background: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and their associated cas genes are sequence-specific DNA nuclease systems found in bacteria and archaea. CRISPR/Cas systems use RNA transcripts of previously acquired DNA (spacers) to target invading genetic elements with the same sequence, including plasmids. In this research we studied the relationship between CRISPR/Cas systems and multidrug resistance in Escherichia coli .
Methods: The presence of Type I-E and Type I-F CRISPR systems was investigated among 82 antimicrobial-susceptible and 96 MDR clinical E. coli isolates by PCR and DNA sequencing. Phylogrouping and MLST were performed to determine relatedness of isolates. RT-PCR was performed to ascertain the expression of associated cas genes.
Results: Type I-F CRISPR was associated with the B2 phylogroup and was significantly overrepresented in the susceptible group (22.0%) compared with the MDR group (2.1%). The majority of CRISPR I-F-containing isolates had spacer sequences that matched IncF and IncI plasmids. RT-PCR demonstrated that Type I-F cas genes were expressed and therefore potentially functional. Conclusions: The CRISPR I-F system is more likely to be found in antimicrobial-susceptible E. coli . Given that the Type I-F system is expressed in WT isolates, we suggest that this difference could be due to the CRISPR system potentially interfering with the acquisition of antimicrobial resistance plasmids, maintaining susceptibility in these isolates.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28535195     DOI: 10.1093/jac/dkx137

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

Review 1.  CRISPR-Cas Biology and Its Application to Infectious Diseases.

Authors:  Jeffrey R Strich; Daniel S Chertow
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

2.  CRISPR-Cas is associated with fewer antibiotic resistance genes in bacterial pathogens.

Authors:  Elizabeth Pursey; Tatiana Dimitriu; Fernanda L Paganelli; Edze R Westra; Stineke van Houte
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2021-11-29       Impact factor: 6.237

Review 3.  The CRISPR conundrum: evolve and maybe die, or survive and risk stagnation.

Authors:  Jesús García-Martínez; Rafael D Maldonado; Noemí M Guzmán; Francisco J M Mojica
Journal:  Microb Cell       Date:  2018-05-16

4.  Characterization of CRISPR-Cas Systems in Clinical Klebsiella pneumoniae Isolates Uncovers Its Potential Association With Antibiotic Susceptibility.

Authors:  Hsin-Yu Li; Cheng-Yen Kao; Wei-Hung Lin; Po-Xing Zheng; Jing-Jou Yan; Ming-Cheng Wang; Ching-Hao Teng; Chin-Chung Tseng; Jiunn-Jong Wu
Journal:  Front Microbiol       Date:  2018-07-16       Impact factor: 5.640

5.  Phenotypic and genomic analyses of bacteriophages targeting environmental and clinical CS3-expressing enterotoxigenic Escherichia coli (ETEC) strains.

Authors:  Sajib Chakraborty; Astrid von Mentzer; Yasmin Ara Begum; Mehnaz Manzur; Mahmudul Hasan; Amar N Ghosh; M Anwar Hossain; Andrew Camilli; Firdausi Qadri
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

6.  CRISPR-Cas influences the acquisition of antibiotic resistance in Klebsiella pneumoniae.

Authors:  Natalie A Mackow; Juntao Shen; Mutayyaba Adnan; Aisha S Khan; Bettina C Fries; Elizabeth Diago-Navarro
Journal:  PLoS One       Date:  2019-11-20       Impact factor: 3.240

7.  Genomic Characterisation of Mushroom Pathogenic Pseudomonads and Their Interaction with Bacteriophages.

Authors:  Nathaniel Storey; Mojgan Rabiey; Benjamin W Neuman; Robert W Jackson; Geraldine Mulley
Journal:  Viruses       Date:  2020-11-10       Impact factor: 5.048

8.  Genomic Insights into Drug Resistance and Virulence Platforms, CRISPR-Cas Systems and Phylogeny of Commensal E. coli from Wildlife.

Authors:  Carla Andrea Alonso; María de Toro; Fernando de la Cruz; Carmen Torres
Journal:  Microorganisms       Date:  2021-05-05

Review 9.  Strategies to combat antimicrobial resistance: anti-plasmid and plasmid curing.

Authors:  Michelle M C Buckner; Maria Laura Ciusa; Laura J V Piddock
Journal:  FEMS Microbiol Rev       Date:  2018-11-01       Impact factor: 16.408

Review 10.  Novel Strategy to Combat Antibiotic Resistance: A Sight into the Combination of CRISPR/Cas9 and Nanoparticles.

Authors:  Fen Wan; Mohamed S Draz; Mengjie Gu; Wei Yu; Zhi Ruan; Qixia Luo
Journal:  Pharmaceutics       Date:  2021-03-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.